Access to HIV prevention becomes a matter of geography rather than need
A quiet expansion of injectable HIV prevention across England's National Health Service has revealed the limits of what progress can mean when cost constrains its reach. Cabotegravir, a long-acting injectable proven to prevent HIV, has been made available to 2,000 people — less than two percent of those already using any form of PrEP — because its price is twenty times that of the daily pill alternative. With no national eligibility standard in place, individual NHS trusts in cities like Leeds and London are writing their own rules about who qualifies, turning a medical question into a geographic lottery. The expansion, in this light, is less a door opening than a narrow gate, and who passes through it may depend less on need than on postcode.
- A drug that works better for some people than daily pills exists — but only 2,000 of England's 111,000 PrEP users will be offered it, exposing the gap between medical possibility and systemic capacity.
- At £7,000 per year versus £350 for generic pills, the cost of cabotegravir has made rationing not a policy failure but a mathematical inevitability.
- With no national eligibility framework, NHS trusts in Leeds and London are independently drafting their own access criteria, creating a patchwork of rules with no shared standard of fairness.
- A person who qualifies for injectable PrEP under one trust's criteria may lose that eligibility simply by moving fifty miles — turning HIV prevention into a matter of geography rather than medicine.
- The populations least able to navigate fragmented local systems — those with fewest resources and least mobility — face the greatest risk of falling through the gaps this rationing creates.
In February, the UK government announced it would make injectable HIV prevention available to 2,000 people through the NHS — double its original commitment. The number sounded like progress. But across England, roughly 111,000 people have ever used any form of PrEP. Two thousand is less than two percent of them.
The drug is cabotegravir, a long-acting injectable administered as two shots every two months. The evidence for its effectiveness is solid. The obstacle is its price: around £7,000 per year at list price, compared to less than £350 annually for generic daily pills. Both prevent HIV. One costs twenty times more than the other. The NHS likely negotiated a discount, but the actual figure remains confidential.
Because supply is limited and budgets are finite, NHS trusts cannot simply open access to all who want it. They must choose. And with no national standard guiding those choices, trusts in different parts of the country are developing their own eligibility criteria. Presentations at a recent joint conference of the British HIV Association and the British Association for Sexual Health and HIV showed how this fragmented approach is already taking shape — one set of rules in Leeds, another in London, and potentially different standards everywhere else.
The consequences are quietly significant. The same person might qualify for injectable PrEP under one trust's criteria and be turned away fifty miles down the road. Access to a more effective prevention tool becomes a function of geography and local budget allocation rather than medical need. Those with the least ability to travel or advocate for themselves are most likely to be left behind.
What was announced as an expansion is, on closer inspection, a rationing exercise framed in the language of progress. The trusts now tasked with implementation are left to answer the harder questions: who qualifies, who doesn't, and whether the answer should ever depend on where someone happens to live.
In February, the UK government quietly expanded its plan for injectable HIV prevention across the National Health Service. Instead of offering the drug to 1,000 people as originally promised, officials announced they would make it available to 2,000. The number sounded like progress until you did the math: across England, roughly 111,000 people have ever started any form of PrEP. Two thousand represents less than 2 percent of them.
The drug in question is cabotegravir, a long-acting injectable given as two shots every two months. It works. The evidence is solid. But the price tag tells the real story of why access will remain so constrained. A year's worth of treatment—six injections—costs around £7,000 at list price. The NHS likely negotiated a discount, but the actual figure remains confidential. Compare that to generic daily pills: tenofovir disoproxil and emtricitabine together cost less than £350 annually. One drug is twenty times more expensive than the other. Both prevent HIV. Only one will be available to most people who need it.
This arithmetic has forced a difficult reckoning across the health service. Because supply is limited and money is finite, individual NHS trusts cannot simply open access to anyone who wants injectable PrEP. They have to choose. They have to decide who gets it and who doesn't. There is no national standard for that decision. Instead, trusts in different parts of the country are developing their own criteria, their own rules about eligibility. Two presentations at the recent joint conference of the British HIV Association and the British Association for Sexual Health and HIV laid bare how this fragmented approach is taking shape on the ground—one set of rules in Leeds, another in London, potentially different standards everywhere else.
The implications ripple outward quietly. A person in one city might qualify for injectable PrEP under their local trust's criteria. That same person, moving fifty miles away, might not. Access to HIV prevention—a tool that works better for some people than daily pills—becomes a matter of geography and local budget allocation rather than medical need or epidemiological logic. The most vulnerable populations, those with the least ability to travel or advocate for themselves, are most likely to fall through the gaps between these local systems.
What began as an expansion—from 1,000 to 2,000 people—reveals itself as a rationing exercise dressed in the language of progress. The NHS has chosen to offer something new to a tiny fraction of those who could benefit from it. The trusts now tasked with implementing that choice are left to sort out the messy human questions: Who deserves access? Who gets left behind? And perhaps most troubling: will the answer depend on where you live?
The Hearth Conversation Another angle on the story
Why did the government expand from 1,000 to 2,000 people if the drug is this expensive?
It's a gesture toward meeting demand without actually meeting it. Two thousand sounds better than one thousand in a press release. But when you're talking about 111,000 existing users, it's still rationing by another name.
So local trusts have to make their own rules about who gets it?
Exactly. There's no national standard. Leeds has one set of criteria, London has another. That creates a patchwork where access depends on your postcode.
What happens to someone who doesn't meet their local criteria?
They stay on daily pills, which work fine for most people. But injectable PrEP is better for some—people with adherence challenges, for instance. Those people lose access to a tool that could help them more, through no fault of their own.
Is cost really the only reason for the limit?
It's the main one. At twenty times the price of pills, the math doesn't work at scale. The NHS could theoretically afford to give it to more people, but then something else doesn't get funded. It's a choice about priorities.
Who ends up disadvantaged by this?
People without the resources to navigate the system, to know about injectable PrEP, to advocate for access. Vulnerable populations. The people who need the most support often get the least.